Using Polyethyline Oxide Blends to Assess the Effect of Excipient Variability - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Using Polyethyline Oxide Blends to Assess the Effect of Excipient Variability
The authors discuss a study that demonstrates the use of polyethylene oxide mixtures to investigate the effect of polymer viscosity on formulation robustness.

Pharmaceutical Technology
Volume 33, Issue 12

Robustness in pharmaceutical solid oral dosage forms means consistently providing the same drug-dissolution performance and shelf life from the dosage form when manufactured within the limits of the defined variations of key quality parameters, which include excipients, active pharmaceutical ingredients (APIs), and the manufacturing process. Under ideal circumstances, formulators would have available to them excipients with a broad range of properties with which to assess the impact of excipient variability on the formulation robustness. Realistically, however, the ability of the supplier to manufacture products at the extremes of a product specification is challenging given that manufacturing processes are designed to operate under optimal process conditions to produce a consistent product.

For polyethylene oxide (PEO), blends may be the answer. When formulating PEO-based matrix systems, the key polymer attributes that affect drug dissolution are polymer viscosity and particle-size distribution. Because PEO does not have the additional complication of chemical substitution seen with many other excipients, blending is a straightforward approach for producing samples for formulation studies, provided the performance of the blended polymer mixture is representative of the standard product. PEO blends can provide a range of samples across a viscosity specification to achieve the necessary variability in product viscosity more easily than using batches of a single PEO product. These samples can then be used to assess the impact of product viscosity variability on formulation properties. This study used two standard PEO products—Polyox 205 National Formulary (NF) water-soluble resins (WSR) and Polyox N-12K NF WSR (Dow Chemical, Midland, MI)—to develop a series of samples across the viscosity-specification range of another standard product, Polyox 1105 NF WSR, which has a viscosity between these two grades. Polymer viscosity, molecular weight, tablet hardness, and drug dissolution were measured to determine the effect of PEO blends on excipient performance in extended-release matrix tablets.


Materials . Excipients used for blending included Polyox 205 NF WSR and Polyox N-12K NF WSR (The Dow Chemical Company) with approximate molecular weights of 6 x 105 and 1 x 106 Da, respectively. Excipients used as standards for comparison were three samples of Polyox 1105 NF WSR (The Dow Chemical Company) with varying solution viscosities with an approximate molecular weight of 9 x 105 Da. The APIs were theophylline and diltiazem hydrochloride (HCl) (Spectrum Chemicals and Laboratory Products, Gardena, CA). Other ingredients included microcrystalline cellulose (MCC, Avicel PH 102, FMC Biopolymer, Newark, DE) and magnesium stearate (Spectrum Chemicals and Laboratory Products).

Table I: Viscosity of polyethylene oxide samples.
Methods . Three blends (25/75, 50/50, and 75/25) were prepared with Polyox 205 NF WSR and Polyox N-12K NF WSR using a mixer (Turbula T2F Heavy Duty Shaker–Mixer, Glen Mills, Clifton, NJ). Viscosity determinations for PEO samples were made using a digital viscometer (Brookfield DV-II+ viscometer, Brookfield Engineering Laboratories, Middleboro, MA), 5% aqueous solution, with spindle 2 at 2 rpm, except for the sample of Polyox N-12K NF WSR, which was run at 2% aqueous solution, spindle 1 at 10 rpm.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here